DK3344628T5 - Terapeutiske forbindelser og syntese - Google Patents

Terapeutiske forbindelser og syntese Download PDF

Info

Publication number: DK3344628T5
Authority: DK; Denmark
Prior art keywords: synthesis; therapeutic compounds; therapeutic; compounds
Prior art date: 2015-09-04

Application number

DK16842976.9T

Other languages

English (en)

Other versions

DK3344628T3 (da

Inventor

Bart Lieven Daniel Decorte

Jacob Cornelis Russcher

Menno Cornelis Franciscus Monnee

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-09-04

Filing date

2016-09-01

Publication date

2021-07-26

2016-09-01 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2020-08-03 Publication of DK3344628T3 publication Critical patent/DK3344628T3/da

2021-07-26 Application granted granted Critical

2021-07-26 Publication of DK3344628T5 publication Critical patent/DK3344628T5/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
- C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
- C07D451/12—Oxygen atoms acylated by aromatic or heteroaromatic carboxylic acids, e.g. cocaine

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Rheumatology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Pyridine Compounds (AREA)

DK16842976.9T 2015-09-04 2016-09-01 Terapeutiske forbindelser og syntese DK3344628T5 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562214727P	2015-09-04	2015-09-04
US201562214734P	2015-09-04	2015-09-04
PCT/US2016/049885 WO2017040772A1 (en)	2015-09-04	2016-09-01	Therapeutic compounds and synthesis

Publications (2)

Publication Number	Publication Date
DK3344628T3 DK3344628T3 (da)	2020-08-03
DK3344628T5 true DK3344628T5 (da)	2021-07-26

Family

ID=58188341

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
DK16842976.9T DK3344628T5 (da)	2015-09-04	2016-09-01	Terapeutiske forbindelser og syntese
DK16842973.6T DK3344626T5 (da)	2015-09-04	2016-09-01	Terapeutiske forbindelser til smerte og syntese deraf
DK16842975.1T DK3344627T5 (da)	2015-09-04	2016-09-01	Terapeutiske forbindelser til smerte og syntese deraf
DK16842971.0T DK3344614T5 (da)	2015-09-04	2016-09-01	Terapeutiske forbindelser til smerte og syntese deraf

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
DK16842973.6T DK3344626T5 (da)	2015-09-04	2016-09-01	Terapeutiske forbindelser til smerte og syntese deraf
DK16842975.1T DK3344627T5 (da)	2015-09-04	2016-09-01	Terapeutiske forbindelser til smerte og syntese deraf
DK16842971.0T DK3344614T5 (da)	2015-09-04	2016-09-01	Terapeutiske forbindelser til smerte og syntese deraf

Country Status (11)

Country	Link
US (9)	US10040795B2 (da)
EP (5)	EP3344628B9 (da)
JP (5)	JP6736661B2 (da)
CN (5)	CN108290890B (da)
CA (5)	CA2997545C (da)
DK (4)	DK3344628T5 (da)
ES (4)	ES2812233T3 (da)
IL (5)	IL257740A (da)
MA (1)	MA45011A (da)
TW (11)	TWI713879B (da)
WO (5)	WO2017040772A1 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6736661B2 (ja) *	2015-09-04	2020-08-05	ヤンセンファーマシューティカエヌ．ベー．	治療化合物及び合成

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1469781A (en) *	1974-06-10	1977-04-06	Boehringer Sohn Ingelheim	Production of scopine
US4232026A (en) *	1978-07-20	1980-11-04	Merck & Co., Inc.	Diazaditwistanes, and pharmaceutical compositions for treating pain in warm blooded animals containing them
US4559157A (en)	1983-04-21	1985-12-17	Creative Products Resource Associates, Ltd.	Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr)	1983-08-30	1985-04-24	Oreal	Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4532244A (en) *	1984-09-06	1985-07-30	Innes Margaret N	Method of treating migraine headaches
US4820508A (en)	1987-06-23	1989-04-11	Neutrogena Corporation	Skin protective composition
US4992478A (en)	1988-04-04	1991-02-12	Warner-Lambert Company	Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en)	1988-09-12	1990-07-03	University Of New York	Treatment of damaged bone marrow and dosage units therefor
JP2514137B2 (ja) *	1990-07-23	1996-07-10	フアイザー・インコーポレイテツド	キヌクリジン誘導体
DE553264T1 (de)	1990-10-05	1994-04-28	Wayne M Barnes	Thermostabile dna polymerase.
US6432976B1 (en) *	1999-10-29	2002-08-13	Merck & Co., Inc.	8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
DE10050994A1 (de) *	2000-10-14	2002-04-18	Boehringer Ingelheim Pharma	Neue als Arneimittel einsetzbare Anticholinergika sowie Verfahren zu deren Herstellung
WO2004106333A1 (en) *	2003-05-28	2004-12-09	Theravance, Inc.	Azabicycloalkane compounds as muscarinic receptor antagonists
ES2356356T3 (es) *	2003-10-15	2011-04-07	Targacept, Inc.	Compuestos azabicíclicos para aliviar el dolor y tratar los trastornos del sistema nervioso central.
ATE482959T1 (de) *	2005-08-22	2010-10-15	Targacept Inc	Heteroarylsubstituierte diazatricycloalkane, verfahren zu deren herstellung und deren anwendung
US8735411B2 (en) *	2006-10-02	2014-05-27	Abbvie Inc.	Macrocyclic benzofused pyrimidine derivatives
WO2008104955A1 (en) *	2007-02-28	2008-09-04	Ranbaxy Laboratories Limited	Azoniatricyclo [3.3.1.0] nonane derivatives as muscarinic receptor antagonists
TW200840569A (en) *	2007-03-13	2008-10-16	Targacept Inc	Sub-type selective amides of diazabicycloalkanes
WO2009124755A1 (en) *	2008-04-08	2009-10-15	European Molecular Biology Laboratory (Embl)	Compounds with novel medical uses and method of identifying such compounds
CN101768158B (zh) *	2010-01-04	2013-05-29	南昌弘益科技有限公司	噻托溴铵无水物及其制备方法
CN102579458A (zh) *	2012-03-08	2012-07-18	冀中能源峰峰集团有限公司总医院	缓解静点药物所致疼痛和防治静脉炎的药品配方
JP6102122B2 (ja) *	2012-08-24	2017-03-29	ソニー株式会社	画像処理装置および方法、並びにプログラム
EP2897948B1 (en) *	2012-09-18	2016-08-31	Heptares Therapeutics Limited	Bicyclic aza compounds as muscarinic m1 receptor agonists
TW201444849A (zh) *	2013-03-13	2014-12-01	Janssen Pharmaceutica Nv	經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
JO3509B1 (ar) *	2013-03-14	2020-07-05	Janssen Pharmaceutica Nv	معدلات p2x7
KR20160115503A (ko) *	2015-03-27	2016-10-06	차의과학대학교 산학협력단	만성 골수성 백혈병 암 줄기세포의 성장 또는 증식 억제용 조성물 및 이의 스크리닝 방법
GB201505654D0 (en) *	2015-04-01	2015-05-13	Nordic Bioscience As	Immunoassay for collagen type VI sequence
GB201505701D0 (en) *	2015-04-02	2015-05-20	Byotrol Plc	Anti-microbial composition
JP6736661B2 (ja) *	2015-09-04	2020-08-05	ヤンセンファーマシューティカエヌ．ベー．	治療化合物及び合成

2016
- 2016-09-01 JP JP2018511607A patent/JP6736661B2/ja not_active Expired - Fee Related
- 2016-09-01 WO PCT/US2016/049885 patent/WO2017040772A1/en not_active Ceased
- 2016-09-01 CN CN201680064673.0A patent/CN108290890B/zh not_active Expired - Fee Related
- 2016-09-01 JP JP2018511670A patent/JP6639651B2/ja not_active Expired - Fee Related
- 2016-09-01 US US15/254,938 patent/US10040795B2/en active Active
- 2016-09-01 DK DK16842976.9T patent/DK3344628T5/da active
- 2016-09-01 JP JP2018511605A patent/JP6736660B2/ja not_active Expired - Fee Related
- 2016-09-01 EP EP16842976.9A patent/EP3344628B9/en active Active
- 2016-09-01 ES ES16842976T patent/ES2812233T3/es active Active
- 2016-09-01 WO PCT/US2016/049881 patent/WO2017040770A1/en not_active Ceased
- 2016-09-01 WO PCT/US2016/049877 patent/WO2017040767A1/en not_active Ceased
- 2016-09-01 WO PCT/US2016/049871 patent/WO2017040764A1/en not_active Ceased
- 2016-09-01 ES ES16842973T patent/ES2807901T3/es active Active
- 2016-09-01 US US15/254,952 patent/US10040796B2/en active Active
- 2016-09-01 CA CA2997545A patent/CA2997545C/en active Active
- 2016-09-01 CA CA2997543A patent/CA2997543C/en active Active
- 2016-09-01 WO PCT/US2016/049893 patent/WO2017040778A1/en not_active Ceased
- 2016-09-01 ES ES16842975T patent/ES2808048T3/es active Active
- 2016-09-01 EP EP16842981.9A patent/EP3344629A4/en not_active Withdrawn
- 2016-09-01 US US15/254,960 patent/US10040797B2/en active Active
- 2016-09-01 MA MA045011A patent/MA45011A/fr unknown
- 2016-09-01 JP JP2018511601A patent/JP6736659B2/ja not_active Expired - Fee Related
- 2016-09-01 EP EP16842973.6A patent/EP3344626B9/en active Active
- 2016-09-01 JP JP2018511626A patent/JP6868008B2/ja not_active Expired - Fee Related
- 2016-09-01 CN CN201680064790.7A patent/CN108349934B/zh not_active Expired - Fee Related
- 2016-09-01 EP EP16842975.1A patent/EP3344627B9/en active Active
- 2016-09-01 US US15/254,965 patent/US10155762B2/en active Active
- 2016-09-01 DK DK16842973.6T patent/DK3344626T5/da active
- 2016-09-01 CA CA2997541A patent/CA2997541C/en active Active
- 2016-09-01 CN CN201680064789.4A patent/CN109071540B/zh not_active Expired - Fee Related
- 2016-09-01 US US15/254,944 patent/US9994572B2/en active Active
- 2016-09-01 CA CA2997501A patent/CA2997501C/en active Active
- 2016-09-01 CN CN201680064788.XA patent/CN109153679B/zh not_active Expired - Fee Related
- 2016-09-01 EP EP16842971.0A patent/EP3344614B9/en active Active
- 2016-09-01 DK DK16842975.1T patent/DK3344627T5/da active
- 2016-09-01 CA CA2997430A patent/CA2997430C/en active Active
- 2016-09-01 ES ES16842971T patent/ES2809703T3/es active Active
- 2016-09-01 DK DK16842971.0T patent/DK3344614T5/da active
- 2016-09-01 CN CN201680064801.1A patent/CN108495854B/zh not_active Expired - Fee Related
- 2016-09-02 TW TW107128718A patent/TWI713879B/zh not_active IP Right Cessation
- 2016-09-02 TW TW107117875A patent/TWI686393B/zh not_active IP Right Cessation
- 2016-09-02 TW TW105128530A patent/TWI636054B/zh not_active IP Right Cessation
- 2016-09-02 TW TW105128531A patent/TWI663167B/zh not_active IP Right Cessation
- 2016-09-02 TW TW105128528A patent/TWI654188B/zh not_active IP Right Cessation
- 2016-09-02 TW TW105128533A patent/TWI641608B/zh not_active IP Right Cessation
- 2016-09-02 TW TW108103711A patent/TWI683815B/zh not_active IP Right Cessation
- 2016-09-02 TW TW107101163A patent/TWI672303B/zh not_active IP Right Cessation
- 2016-09-02 TW TW106142501A patent/TWI695836B/zh not_active IP Right Cessation
- 2016-09-02 TW TW107120678A patent/TWI707854B/zh not_active IP Right Cessation
- 2016-09-02 TW TW105128529A patent/TWI639597B/zh not_active IP Right Cessation
2018
- 2018-02-26 IL IL257740A patent/IL257740A/en active IP Right Grant
- 2018-02-26 IL IL257732A patent/IL257732B/en active IP Right Grant
- 2018-02-26 IL IL257735A patent/IL257735B/en unknown
- 2018-02-26 IL IL257737A patent/IL257737B2/en unknown
- 2018-02-26 IL IL257734A patent/IL257734B/en unknown
- 2018-06-11 US US16/005,366 patent/US10351565B2/en active Active
- 2018-07-24 US US16/043,813 patent/US10351566B2/en active Active
- 2018-07-24 US US16/043,829 patent/US10358448B2/en active Active
- 2018-12-17 US US16/222,852 patent/US10766898B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
IL257737A (en)	2018-04-30
ES2809703T3 (es)	2021-03-05
TW201716409A (zh)	2017-05-16
US10766898B2 (en)	2020-09-08
EP3344614B1 (en)	2020-07-08
CN108495854B (zh)	2021-10-15
EP3344627B1 (en)	2020-07-01
EP3344628A1 (en)	2018-07-11
TWI641608B (zh)	2018-11-21
JP6736661B2 (ja)	2020-08-05
IL257734B (en)	2021-07-29
US10351565B2 (en)	2019-07-16
TW201819381A (zh)	2018-06-01
US20170066760A1 (en)	2017-03-09
TWI695836B (zh)	2020-06-11
EP3344626A4 (en)	2019-03-27
TW201722951A (zh)	2017-07-01
EP3344629A4 (en)	2019-03-27
WO2017040770A1 (en)	2017-03-09
IL257740A (en)	2018-04-30
ES2809703T9 (es)	2022-01-24
IL257734A (en)	2018-04-30
EP3344626A1 (en)	2018-07-11
TWI654188B (zh)	2019-03-21
CN108290890B (zh)	2021-08-06
TWI686393B (zh)	2020-03-01
WO2017040772A9 (en)	2019-03-07
EP3344628B1 (en)	2020-07-15
EP3344627B9 (en)	2021-08-04
EP3344628A4 (en)	2019-03-27
IL257735A (en)	2018-04-30
EP3344626B1 (en)	2020-07-08
EP3344614A1 (en)	2018-07-11
IL257732B (en)	2020-11-30
ES2807901T9 (es)	2022-01-31
TWI672303B (zh)	2019-09-21
TW201833110A (zh)	2018-09-16
CA2997501C (en)	2022-05-10
CA2997543C (en)	2022-07-19
US10040796B2 (en)	2018-08-07
IL257735B (en)	2022-01-01
CN108349934A (zh)	2018-07-31
TW201722954A (zh)	2017-07-01
IL257737B2 (en)	2023-02-01
IL257737B (en)	2022-10-01
JP2018527356A (ja)	2018-09-20
WO2017040778A1 (en)	2017-03-09
US10040795B2 (en)	2018-08-07
EP3344628B9 (en)	2021-06-30
US20180327405A1 (en)	2018-11-15
TW201920176A (zh)	2019-06-01
TWI639597B (zh)	2018-11-01
JP6639651B2 (ja)	2020-02-05
ES2808048T3 (es)	2021-02-25
US10155762B2 (en)	2018-12-18
US20180327406A1 (en)	2018-11-15
TWI713879B (zh)	2020-12-21
DK3344627T3 (da)	2020-07-20
DK3344614T3 (da)	2020-07-27
WO2017040764A1 (en)	2017-03-09
DK3344614T5 (da)	2021-08-30
DK3344627T5 (da)	2021-08-30
CN108290890A (zh)	2018-07-17
CA2997501A1 (en)	2017-03-09
TWI663167B (zh)	2019-06-21
US20180291024A1 (en)	2018-10-11
US10358448B2 (en)	2019-07-23
CN109153679B (zh)	2022-04-08
CN109153679A (zh)	2019-01-04
TWI636054B (zh)	2018-09-21
WO2017040772A1 (en)	2017-03-09
TW201843153A (zh)	2018-12-16
TW201722955A (zh)	2017-07-01
EP3344627A4 (en)	2019-03-27
JP6868008B2 (ja)	2021-05-12
DK3344626T3 (da)	2020-07-27
TWI707854B (zh)	2020-10-21
CA2997430C (en)	2021-05-11
JP2018527355A (ja)	2018-09-20
JP2018526387A (ja)	2018-09-13
CN108349934B (zh)	2021-10-22
EP3344614A4 (en)	2019-03-27
JP6736659B2 (ja)	2020-08-05
DK3344626T5 (da)	2021-09-06
US20170066768A1 (en)	2017-03-09
CA2997541A1 (en)	2017-03-09
JP2018531907A (ja)	2018-11-01
JP6736660B2 (ja)	2020-08-05
EP3344627A1 (en)	2018-07-11
ES2812233T9 (es)	2022-02-18
US20170066769A1 (en)	2017-03-09
ES2808048T9 (es)	2022-02-01
US9994572B2 (en)	2018-06-12
MA45011A (fr)	2021-06-02
CA2997541C (en)	2022-01-11
CN109071540B (zh)	2021-06-04
TW201835082A (zh)	2018-10-01
US20190112311A1 (en)	2019-04-18
US10351566B2 (en)	2019-07-16
DK3344628T3 (da)	2020-08-03
CN109071540A (zh)	2018-12-21
TW201722953A (zh)	2017-07-01
CA2997543A1 (en)	2017-03-09
US20170066770A1 (en)	2017-03-09
CA2997430A1 (en)	2017-03-09
IL257732A (en)	2018-04-30
EP3344629A1 (en)	2018-07-11
CA2997545A1 (en)	2017-03-09
CN108495854A (zh)	2018-09-04
US10040797B2 (en)	2018-08-07
CA2997545C (en)	2022-01-11
EP3344614B9 (en)	2021-07-28
ES2812233T3 (es)	2021-03-16
ES2807901T3 (es)	2021-02-24
WO2017040767A1 (en)	2017-03-09
EP3344626B9 (en)	2021-08-11
TW201811786A (zh)	2018-04-01
TWI683815B (zh)	2020-02-01
US20170066767A1 (en)	2017-03-09
JP2018526388A (ja)	2018-09-13

Publication	Publication Date	Title
DK3283106T3 (da)	2022-01-10	Terapeutiske antistoffer og anvendelser deraf
DK3888658T3 (da)	2024-03-18	Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil
DK3354282T3 (da)	2021-03-08	Glycan-terapeutiske midler og relaterede fremgangsmåder deraf
EP3463464A4 (en)	2020-07-01	ASSOCIATION TREATMENT
DK3328880T3 (da)	2021-08-30	Terapeutiske midler
DK3317284T3 (da)	2020-01-13	Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3310371T3 (da)	2020-10-12	Glucagon og GLP-1-Co-agonistforbindelser
DK3495023T3 (da)	2020-07-20	Semifluorerede forbindelser og sammensætninger deraf
DK3215147T3 (da)	2024-04-02	Neurodæmpende norketamin-forbindelser og fremgangsmåder
DK3294770T3 (da)	2020-12-07	Terapeutiske og diagnostiske fremgangsmåder til cancer
DK3155024T3 (da)	2020-11-23	Opholdsstrukturer og relaterede fremgangsmåder
DK3210977T3 (da)	2019-07-01	Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf
DK3102200T3 (da)	2023-05-22	Terapeutisk forbindelse og sammensætning
DK3183260T3 (da)	2021-06-21	Modificerede oligonukleotider og fremgangsmåder til deres syntese
DK3357513T3 (da)	2023-11-27	Farmaceutisk sammensætning og anvendelse deraf
DK3218358T3 (da)	2021-08-30	Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3723488T3 (da)	2025-10-27	Terapeutiske bakteriociner
DK3389669T3 (da)	2023-05-01	Triterpensaponinvarianter, syntesefremgangsmåder og anvendelse deraf
DK3408265T3 (da)	2020-06-02	Terapeutiske forbindelser
DK3321279T3 (da)	2020-03-09	Exenatidmodificeringsmiddel og anvendelse deraf
IL262851A (en)	2018-12-31	Combination prime: boost therapy
DK3393478T3 (da)	2020-03-23	Kombinationsterapi
DK3615502T3 (da)	2023-09-25	Terapeutiske forbindelser og fremgangsmåder
DK3256479T3 (da)	2020-11-02	4-substituerede benzoxaborolforbindelser og anvendelser deraf
DK3365321T3 (da)	2024-01-15	Solabegron-zwitterion og anvendelser deraf